https://www.coltonconsortium.org/projects/the-role-of-glycosylation-in-inflammatory-bowel-disease/
Investigating how foreign sugar modifications on anti-TNF biologics trigger immune responses in pediatric IBD patients, this project aims to personalize biologic therapy selection and inform safer drug design.
https://www.coltonconsortium.org/projects/a-data-driven-framework-for-predicting-and-managing-flares-in-inflammatory-bowel-disease/
Combining machine learning with microbiome and metabolomic data from 4,000+ IBD patients, this project develops tools to predict disease flares, identify therapeutic targets, and enable personalized flare prevention.
https://www.coltonconsortium.org/projects/shedding-light-on-the-invisible-a-new-paradigm-for-predicting-multiple-sclerosis-disease-progression-using-novel-mri-tools-for-probing-pathology-in-normal-appearing-tissues/
Applying advanced quantitative MRI to detect pathology invisible to current clinical tools, this project builds an AI model to predict MS progression and enable earlier, more personalized diagnosis and treatment.
https://www.coltonconsortium.org/projects/novel-tools-to-track-and-manipulate-immune-cells-in-autoimmunity-models/
Developing a cell-labeling tool to map immune cell interactions in living tissue, this project identifies the drivers of skin-resident T cell persistence in psoriasis and potential targets for disease prevention.
https://www.coltonconsortium.org/projects/early-detection-and-diagnosis-of-autoimmune-diseases-using-foundation-ai-models/
Applying self-supervised AI to multi-modal electronic health records — integrating clinical notes, labs, and imaging — this project builds scalable diagnostic models to detect autoimmune diseases earlier and more precisely.
https://www.coltonconsortium.org/projects/developing-new-mode-of-action-calcineurin-inhibitors-for-acute-colitis-therapeutics/
Targeting the calcineurin-NFAT protein-protein interaction rather than enzyme active sites, this project develops a novel class of inhibitors to treat steroid-refractory ulcerative colitis with fewer side effects.
https://www.coltonconsortium.org/projects/the-epidermis-as-a-novel-therapeutic-target-in-pemphigus-vulgaris/
By profiling genetic and molecular drivers of pemphigus vulgaris across patient skin and blood, this project uncovers genotype-driven inflammatory loops and actionable targets for personalized therapy.
https://www.coltonconsortium.org/projects/developing-a-multi-parameter-prognostic-prediction-model-for-disability-ranks-and-progression-of-patients-with-multiple-sclerosis-at-the-early-stages-of-the-disease/
Integrating clinical, imaging, and biological data from large real-world MS cohorts, this project builds a machine learning model to predict disability progression early and enable personalized treatment decisions.
https://www.coltonconsortium.org/projects/immunotherapy-related-adverse-effects-as-models-for-fragile-tolerance-in-humans/
Using cancer patients experiencing immunotherapy-triggered autoimmunity as a unique human model, this project uncovers the molecular and epigenetic mechanisms by which self-reactive T cells escape immune tolerance.
https://www.coltonconsortium.org/projects/inhibiting-netosis-with-nuclear-penetrating-antibodies/
Repurposing nuclear-penetrating autoantibodies from lupus and scleroderma patients as potent, safe inhibitors of pathogenic NETosis.